Viral Hepatitis Global Market is Booming Across the Globe and Witness Huge Growth By Key Players To 2033 | The Business Research Company

Spread the love

Overview and Scope
Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.

Sizing and Forecast
The viral hepatitis market size has grown steadily in recent years. It will grow from $15.48 billion in 2023 to $16.21 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to vaccine development, blood screening programs, antiviral drugs, global health initiatives.

The viral hepatitis market size is expected to see steady growth in the next few years. It will grow to $19.01 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to access to treatment, public health legislation, combination therapies, health equity initiatives. Major trends in the forecast period include personalized treatment plans, digital health tools, ai in disease monitoring, hepatitis c micro-elimination.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Segmentation & Regional Insights
The viral hepatitis market covered in this report is segmented –
1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
2) By Diagnosis: Liver Biopsy; Blood Tests; Imaging Tests; Other Diagnosis
3) By Treatment: Antiviral Drugs; Surgery; Vaccine; Immune Modulator Drugs; Other Treatments
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

North America was the largest region in the viral hepatitis market in 2023. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Major Driver Impacting Market Growth
The rising prevalence of hepatitis is expected to propel the growth of the viral hepatitis market going forward. Hepatitis is an infection of the liver caused by several infectious viruses and non-infectious substances, which can result in several medical issues. Hepatitis A, B, C, D and E are among the viruses that can cause viral hepatitis, which results in liver inflammation and damage. For instance, in August 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, there were about 9,952 hepatitis A cases reported by 49 states and the District of Columbia in 2020 and 4,798 acute hepatitis C cases were reported to CDC from 44 states in 2020. Further, in 2020, 41 states reported a total of 107,300 newly discovered cases of chronic hepatitis C to the CDC. Therefore, the rising prevalence of hepatitis will drive the viral hepatitis market.

Key Industry Players
Major players in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd. .

The viral hepatitis market report table of contents includes:
1. Executive Summary